Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Design, Synthesis, and Pharmacological Evaluation of Novel β2/3 Subunit-Selective γ-Aminobutyric Acid Type A (GABAA) Receptor Modulators.

Stadler M, Monticelli S, Seidel T, Luger D, Salzer I, Boehm S, Holzer W, Schwarzer C, Urban E, Khom S, Langer T, Pace V, Hering S.

J Med Chem. 2019 Jan 10;62(1):317-341. doi: 10.1021/acs.jmedchem.8b00859. Epub 2018 Oct 23.

PMID:
30289721
3.

Paracrine-Mediated Systemic Anti-Inflammatory Activity of Intravenously Administered Mesenchymal Stem Cells: A Transformative Strategy for Cardiac Stem Cell Therapeutics.

Epstein SE, Luger D, Lipinski MJ.

Circ Res. 2017 Oct 13;121(9):1044-1046. doi: 10.1161/CIRCRESAHA.117.311925. No abstract available.

PMID:
29025759
4.

Large Animal Model Efficacy Testing Is Needed Prior to Launch of a Stem Cell Clinical Trial: An Evidence-Lacking Conclusion Based on Conjecture.

Epstein SE, Luger D, Lipinski MJ.

Circ Res. 2017 Aug 18;121(5):496-498. doi: 10.1161/CIRCRESAHA.117.311562. Review. No abstract available.

PMID:
28819039
5.

Mesenchymal Stem Cell Therapy for the Treatment of Heart Failure Caused by Ischemic or Non-ischemic Cardiomyopathy: Immunosuppression and Its Implications.

Lipinski MJ, Luger D, Epstein SE.

Handb Exp Pharmacol. 2017;243:329-353. doi: 10.1007/164_2017_23. Review.

PMID:
28382469
6.

Intravenously Delivered Mesenchymal Stem Cells: Systemic Anti-Inflammatory Effects Improve Left Ventricular Dysfunction in Acute Myocardial Infarction and Ischemic Cardiomyopathy.

Luger D, Lipinski MJ, Westman PC, Glover DK, Dimastromatteo J, Frias JC, Albelda MT, Sikora S, Kharazi A, Vertelov G, Waksman R, Epstein SE.

Circ Res. 2017 May 12;120(10):1598-1613. doi: 10.1161/CIRCRESAHA.117.310599. Epub 2017 Feb 23.

PMID:
28232595
7.

Analysis of β-Subunit-dependent GABAA Receptor Modulation and Behavioral Effects of Valerenic Acid Derivatives.

Khom S, Hintersteiner J, Luger D, Haider M, Pototschnig G, Mihovilovic MD, Schwarzer C, Hering S.

J Pharmacol Exp Ther. 2016 Jun;357(3):580-90. doi: 10.1124/jpet.116.232983. Epub 2016 Apr 18.

8.

Inflammation as a Driver of Adverse Left Ventricular Remodeling After Acute Myocardial Infarction.

Westman PC, Lipinski MJ, Luger D, Waksman R, Bonow RO, Wu E, Epstein SE.

J Am Coll Cardiol. 2016 May 3;67(17):2050-60. doi: 10.1016/j.jacc.2016.01.073. Review.

9.

Shock Index as a predictor for In-hospital mortality in patients with non-ST-segment elevation myocardial infarction.

Kobayashi A, Misumida N, Luger D, Kanei Y.

Cardiovasc Revasc Med. 2016 Jun;17(4):225-8. doi: 10.1016/j.carrev.2016.02.015. Epub 2016 Feb 27.

PMID:
26973283
10.

Multimodality imaging demonstrates trafficking of liposomes preferentially to ischemic myocardium.

Lipinski MJ, Albelda MT, Frias JC, Anderson SA, Luger D, Westman PC, Escarcega RO, Hellinga DG, Waksman R, Arai AE, Epstein SE.

Cardiovasc Revasc Med. 2016 Mar;17(2):106-12. doi: 10.1016/j.carrev.2016.01.003. Epub 2016 Jan 21.

11.

Mechanisms Contributing to the Progression of Ischemic and Nonischemic Dilated Cardiomyopathy: Possible Modulating Effects of Paracrine Activities of Stem Cells.

Kelkar AA, Butler J, Schelbert EB, Greene SJ, Quyyumi AA, Bonow RO, Cohen I, Gheorghiade M, Lipinski MJ, Sun W, Luger D, Epstein SE.

J Am Coll Cardiol. 2015 Nov 3;66(18):2038-2047. doi: 10.1016/j.jacc.2015.09.010. Review.

12.

Identification of the putative binding pocket of valerenic acid on GABAA receptors using docking studies and site-directed mutagenesis.

Luger D, Poli G, Wieder M, Stadler M, Ke S, Ernst M, Hohaus A, Linder T, Seidel T, Langer T, Khom S, Hering S.

Br J Pharmacol. 2015 Nov;172(22):5403-13. doi: 10.1111/bph.13329. Epub 2015 Oct 25.

13.

Abnormal P-Wave Terminal Force in Lead V1 Predicts Left Main and/or Three-Vessel Disease in Patients with Non-ST-Segment Elevation Myocardial Infarction P-Wave Abnormality and Extensive Coronary Artery Disease.

Kobayashi A, Misumida N, Luger D, Kanei Y.

Ann Noninvasive Electrocardiol. 2015 Nov;20(6):612-3. doi: 10.1111/anec.12290. Epub 2015 Jul 14. No abstract available.

PMID:
26178708
14.

Detection of differential fetal and adult expression of chloride intracellular channel 4 (CLIC4) protein by analysis of a green fluorescent protein knock-in mouse line.

Padmakumar V, Masiuk KE, Luger D, Lee C, Coppola V, Tessarollo L, Hoover SB, Karavanova I, Buonanno A, Simpson RM, Yuspa SH.

BMC Dev Biol. 2014 May 28;14:24. doi: 10.1186/1471-213X-14-24.

15.

Esters of valerenic acid as potential prodrugs.

Hintersteiner J, Haider M, Luger D, Schwarzer C, Reznicek G, Jäger W, Khom S, Mihovilovic MD, Hering S.

Eur J Pharmacol. 2014 Jul 15;735:123-31. doi: 10.1016/j.ejphar.2014.03.019. Epub 2014 Mar 27.

16.

Expression of the B-cell receptor component CD79a on immature myeloid cells contributes to their tumor promoting effects.

Luger D, Yang YA, Raviv A, Weinberg D, Banerjee S, Lee MJ, Trepel J, Yang L, Wakefield LM.

PLoS One. 2013 Oct 16;8(10):e76115. doi: 10.1371/journal.pone.0076115. eCollection 2013.

17.

Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.

Bennett CN, Tomlinson CC, Michalowski AM, Chu IM, Luger D, Mittereder LR, Aprelikova O, Shou J, Piwinica-Worms H, Caplen NJ, Hollingshead MG, Green JE.

Breast Cancer Res. 2012 Jul 19;14(4):R109. doi: 10.1186/bcr3230.

18.

Effects of large hiatal hernias on esophageal peristalsis.

Roman S, Kahrilas PJ, Kia L, Luger D, Soper N, Pandolfino JE.

Arch Surg. 2012 Apr;147(4):352-7. doi: 10.1001/archsurg.2012.17.

19.

Phenotypes and clinical context of hypercontractility in high-resolution esophageal pressure topography (EPT).

Roman S, Pandolfino JE, Chen J, Boris L, Luger D, Kahrilas PJ.

Am J Gastroenterol. 2012 Jan;107(1):37-45. doi: 10.1038/ajg.2011.313. Epub 2011 Sep 20.

20.

GATA3 inhibits lysyl oxidase-mediated metastases of human basal triple-negative breast cancer cells.

Chu IM, Michalowski AM, Hoenerhoff M, Szauter KM, Luger D, Sato M, Flanders K, Oshima A, Csiszar K, Green JE.

Oncogene. 2012 Apr 19;31(16):2017-27. doi: 10.1038/onc.2011.382. Epub 2011 Sep 5.

21.

Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101.

Bar-Yehuda S, Luger D, Ochaion A, Cohen S, Patokaa R, Zozulya G, Silver PB, de Morales JM, Caspi RR, Fishman P.

Int J Mol Med. 2011 Nov;28(5):727-31. doi: 10.3892/ijmm.2011.753. Epub 2011 Jul 19.

22.

High-resolution manometry studies are frequently imperfect but usually still interpretable.

Roman S, Kahrilas PJ, Boris L, Bidari K, Luger D, Pandolfino JE.

Clin Gastroenterol Hepatol. 2011 Dec;9(12):1050-5. doi: 10.1016/j.cgh.2011.08.007. Epub 2011 Aug 18. Review.

23.

Distal esophageal spasm in high-resolution esophageal pressure topography: defining clinical phenotypes.

Pandolfino JE, Roman S, Carlson D, Luger D, Bidari K, Boris L, Kwiatek MA, Kahrilas PJ.

Gastroenterology. 2011 Aug;141(2):469-75. doi: 10.1053/j.gastro.2011.04.058. Epub 2011 May 6.

24.

Mechanical properties of the esophagus in eosinophilic esophagitis.

Kwiatek MA, Hirano I, Kahrilas PJ, Rothe J, Luger D, Pandolfino JE.

Gastroenterology. 2011 Jan;140(1):82-90. doi: 10.1053/j.gastro.2010.09.037. Epub 2010 Sep 19.

25.

The contractile deceleration point: an important physiologic landmark on oesophageal pressure topography.

Pandolfino JE, Leslie E, Luger D, Mitchell B, Kwiatek MA, Kahrilas PJ.

Neurogastroenterol Motil. 2010 Apr;22(4):395-400, e90. doi: 10.1111/j.1365-2982.2009.01443.x. Epub 2009 Dec 27.

26.

Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response.

Tang J, Zhou R, Luger D, Zhu W, Silver PB, Grajewski RS, Su SB, Chan CC, Adorini L, Caspi RR.

J Immunol. 2009 Apr 15;182(8):4624-32. doi: 10.4049/jimmunol.0801543.

27.

Inhibitory peptide analogs derived from a major uveitogenic epitope protect from antiretinal autoimmunity by inducing type 2 and regulatory T cells.

Cortes LM, Avichezer D, Silver PB, Luger D, Mattapallil MJ, Chan CC, Caspi RR.

J Leukoc Biol. 2008 Aug;84(2):577-85. doi: 10.1189/jlb.0308189. Epub 2008 May 21.

28.

Mouse models of experimental autoimmune uveitis.

Caspi RR, Silver PB, Luger D, Tang J, Cortes LM, Pennesi G, Mattapallil MJ, Chan CC.

Ophthalmic Res. 2008;40(3-4):169-74. doi: 10.1159/000119871. Epub 2008 Apr 18. Review.

29.

Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category.

Luger D, Silver PB, Tang J, Cua D, Chen Z, Iwakura Y, Bowman EP, Sgambellone NM, Chan CC, Caspi RR.

J Exp Med. 2008 Apr 14;205(4):799-810. doi: 10.1084/jem.20071258. Epub 2008 Apr 7.

30.

Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion.

Rachitskaya AV, Hansen AM, Horai R, Li Z, Villasmil R, Luger D, Nussenblatt RB, Caspi RR.

J Immunol. 2008 Apr 15;180(8):5167-71.

31.

New perspectives on effector mechanisms in uveitis.

Luger D, Caspi RR.

Semin Immunopathol. 2008 Apr;30(2):135-43. doi: 10.1007/s00281-008-0108-5. Epub 2008 Mar 4. Review.

32.

Hydrodynamic vaccination with DNA encoding an immunologically privileged retinal antigen protects from autoimmunity through induction of regulatory T cells.

Silver PB, Agarwal RK, Su SB, Suffia I, Grajewski RS, Luger D, Chan CC, Mahdi RM, Nickerson JM, Caspi RR.

J Immunol. 2007 Oct 15;179(8):5146-58.

33.

The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model.

Sharabi A, Luger D, Ben-David H, Dayan M, Zinger H, Mozes E.

J Immunol. 2007 Oct 15;179(8):4979-87.

34.

Altered chemokine profile associated with exacerbated autoimmune pathology under conditions of genetic interferon-gamma deficiency.

Su SB, Grajewski RS, Luger D, Agarwal RK, Silver PB, Tang J, Tuo J, Chan CC, Caspi RR.

Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4616-25.

36.

Ventilation, sensible heat loss, broiler energy, and water balance under harsh environmental conditions.

Yahav S, Straschnow A, Luger D, Shinder D, Tanny J, Cohen S.

Poult Sci. 2004 Feb;83(2):253-8.

PMID:
14979577
37.
38.

Hyper- or hypothyroidism: its association with the development of ascites syndrome in fast-growing chickens.

Luger D, Shinder D, Yahav S.

Gen Comp Endocrinol. 2002 Jul;127(3):293-9.

PMID:
12225772
39.

Association between weight gain, blood parameters, and thyroid hormones and the development of ascites syndrome in broiler chickens.

Luger D, Shinder D, Rzepakovsky V, Rusal M, Yahav S.

Poult Sci. 2001 Jul;80(7):965-71.

PMID:
11469663
40.

Thermoregulation in naked neck chickens subjected to different ambient temperatures.

Yahav S, Luger D, Cahaner A, Dotan M, Rusal M, Hurwitz S.

Br Poult Sci. 1998 Mar;39(1):133-8.

PMID:
9568311
41.

Smoke out.

Luger D.

Health Syst Rev. 1997 Jan-Feb;30(1):11-2, 15.

PMID:
10166177
42.

Occupational therapy goes home.

Luger D.

Rehab Manag. 1996 Apr-May;9(3):42-3. No abstract available.

PMID:
10166567
43.

Physician retraining in primary care.

Luger DL.

Health Syst Rev. 1995 Mar-Apr;28(2):30, 32, 34-5.

PMID:
10141121
44.

The use of deep frozen, stored bovine blood for in vitro feeding of tsetse flies.

Wetzel H, Luger D.

Z Parasitenkd. 1978 Oct 31;57(2):163-8.

PMID:
735304
45.
46.

A preliminary report on the establishment of a G. morsitans orientalis Vanderplank colony fed on membranes with rabbit supplement.

Mews AR, Baumgartner H, Luger D, Offori ED.

Trans R Soc Trop Med Hyg. 1973;67(2):291-2. No abstract available.

PMID:
4784096

Supplemental Content

Support Center